NZ538808A - Vaccines against west nile virus - Google Patents

Vaccines against west nile virus

Info

Publication number
NZ538808A
NZ538808A NZ538808A NZ53880803A NZ538808A NZ 538808 A NZ538808 A NZ 538808A NZ 538808 A NZ538808 A NZ 538808A NZ 53880803 A NZ53880803 A NZ 53880803A NZ 538808 A NZ538808 A NZ 538808A
Authority
NZ
New Zealand
Prior art keywords
west nile
nile virus
cell
virus
per
Prior art date
Application number
NZ538808A
Other languages
English (en)
Inventor
Alphonsus Gerardus C Uytdehaag
Govert Johan Schouten
Jaap Goudsmit
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of NZ538808A publication Critical patent/NZ538808A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ538808A 2002-11-08 2003-11-07 Vaccines against west nile virus NZ538808A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NLPCT/NL02/00718 2002-11-08
EPPCT/EP03/50129 2003-04-28
PCT/EP2003/050806 WO2004042042A1 (en) 2002-11-08 2003-11-07 Vaccines against west nile virus

Publications (1)

Publication Number Publication Date
NZ538808A true NZ538808A (en) 2008-03-28

Family

ID=32313778

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ538808A NZ538808A (en) 2002-11-08 2003-11-07 Vaccines against west nile virus

Country Status (7)

Country Link
AT (1) ATE453708T1 (de)
AU (1) AU2003298277B2 (de)
CA (1) CA2501220C (de)
DE (1) DE60330795D1 (de)
IL (1) IL168374A (de)
NZ (1) NZ538808A (de)
WO (1) WO2004042042A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1583949B1 (de) 2002-10-16 2015-06-17 Gen-Probe Incorporated Zusammensetzungen und verfahren zumnachweis des west-nil-virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
EP1724338A1 (de) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methode zur Herstellung eines Impfstoffs aus inaktiviertem ganzem Westnilvirus
CN101222936A (zh) * 2005-06-24 2008-07-16 英特威国际有限公司 灭活的嵌合疫苗和相关的使用方法
ATE463559T1 (de) 2005-07-22 2010-04-15 Crucell Holland Bv Zelllinie zur produktion von coronaviren

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1103610A1 (de) * 1999-11-26 2001-05-30 Introgene B.V. Impfstoffherstellung von immortalisierten Säugetierzellinien
US20030148261A1 (en) * 2001-03-12 2003-08-07 Erol Fikrig Compositions and methods comprising West Nile virus polypeptides

Also Published As

Publication number Publication date
DE60330795D1 (de) 2010-02-11
AU2003298277B2 (en) 2009-01-22
CA2501220C (en) 2012-01-17
WO2004042042A1 (en) 2004-05-21
IL168374A (en) 2010-11-30
ATE453708T1 (de) 2010-01-15
AU2003298277A1 (en) 2004-06-07
CA2501220A1 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
Powers Vaccine and therapeutic options to control chikungunya virus
US11753627B2 (en) Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
US7425437B2 (en) Vaccines against West Nile Virus
Srivastava et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells
CN103031279B (zh) 重组黄病毒疫苗
US20130095136A1 (en) Tetravalent Dengue Vaccines
Pereira et al. An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures
Tretyakova et al. Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine
US20080131460A1 (en) Method of Immunization Against the 4 Serotypes of Dengue Fever
WO2007094854A9 (en) Rna virus vaccines and methods
US10653769B2 (en) iDNA vaccines and methods for using the same
CN108289945B (zh) 用于制备减毒四价登革热疫苗的方法
Gaspar et al. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development
CN102533675A (zh) 表达尼帕脑炎病毒F蛋白的重组新城疫病毒LaSota疫苗株
AU2003298277B2 (en) Vaccines against West Nile Virus
US20150231226A1 (en) Novel attenuated dengue virus strains for vaccine application
EP1558726B1 (de) Impfstoff gegen west nile virus
RU2795800C1 (ru) Иммунобиологическое средство для профилактики заболеваний, вызванных вирусом клещевого энцефалита на основе рекомбинантного вируса рода Flavivirus
Williamson Poxvirus DNA-dependent RNA polymerase
Kuznetsova et al. Development and Characterization of Yellow Fever Virus Vaccine Strain 17DD-Based Chimeric Tick-Borne Encephalitis Virus
Rodríguez et al. Vaccine composition
CN105695424A (zh) 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 NOV 2016 BY COMPUTER PACKAGES INC

Effective date: 20131126

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 NOV 2017 BY CPA GLOBAL

Effective date: 20160930

LAPS Patent lapsed